Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aker BioMarine ASA ( (DE:1PG) ) has issued an announcement.
Aker BioMarine reported a strong second quarter in 2025, with a 12% increase in revenue to USD 55.3 million and a 41% rise in adjusted EBITDA. The Human Health Ingredients segment led the growth with a 15% revenue increase, driven by demand in China and Asia Pacific. Consumer Health Products also saw a 9% revenue rise, supported by products like Sam’s Club Multivitamin Gummies and Costco Taiwan. The company is focusing on cost efficiency and adapting to market trends amid macroeconomic uncertainties, while its Emerging Business segment is progressing towards cash break-even.
More about Aker BioMarine ASA
Aker BioMarine is a leading innovator in human health and nutrition, specializing in krill-derived products sourced from Antarctica. The company offers a diverse portfolio that includes Superba Krill Oil, Lysoveta, FloraMarine, and PL+, alongside the consumer brand Kori Krill. Aker BioMarine is also involved in sustainability initiatives through its spin-offs AION and Understory. The company is publicly traded on the Oslo Stock Exchange.
Average Trading Volume: 21,477
Current Market Cap: NOK5.71B
See more insights into 1PG stock on TipRanks’ Stock Analysis page.